Lupkynis (voclosporin) — Recommended Authorization Criteria
Customize your policy alerts
Sign up for all medical mutual - ohio policy alerts
Know when medical mutual - ohio releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization guidance for outpatient pharmacy coverage of Lupkynis (voclosporin) for adults with active lupus nephritis, including initial and continuation criteria, prescriber requirements, and conditions not recommended for approval.
No material clinical or coverage changes in this revision.
Coverage Criteria for Lupkynis (voclosporin)
Initial Therapy
Covered when ALL of the following are met:
Examples: WHO class III, IV, or V lupus nephritis; immunosuppressive regimen examples include azathioprine, cyclophosphamide, leflunomide, methotrexate, mycophenolate mofetil, and/or systemic corticosteroid.
Continuation / Currently Receiving Lupkynis
Approve for 1 year when ALL of the following are met:
Examples of response include improvement in organ dysfunction, reduction in flares, reduction in corticosteroid dose, decrease of anti-dsDNA titer, and improvement in complement levels (C3, C4).
Concurrent use of Lupkynis with other biologic therapies or with cyclophosphamide is not recommended. The policy states that Lupkynis has not been studied in combination with biologics or cyclophosphamide and that safety and efficacy have not been established for these combinations; an appendix provides examples of biologics that should not be combined with Lupkynis.
Use of voclosporin (Lupkynis) for plaque psoriasis is not recommended. A Phase III trial showed voclosporin was inferior to cyclosporine, and multiple other FDA‑approved therapies with established efficacy are available for this indication.
Coverage is not recommended for any situation that is not explicitly listed in the Recommended Authorization Criteria. The policy notes that the listed conditions and criteria define the circumstances for which approval is supported and will be updated as new published data become available.
The Company may deny reimbursement when the drug or related services are determined to be not medically necessary, investigational or experimental, or not within the scope of member benefits. The Company also reserves the right to deny payment for inappropriate or excessive billing patterns and may request supporting documentation (for example, patient records, test results, or provider credentials) to substantiate medical necessity.
Clinical Thresholds and Coding Notes
Prescriber Requirements and Documentation
Prior authorization required — specialist prescriber/consult and time-limited approvals
Prior authorization is required for pharmacy coverage of Lupkynis. Initial approvals are time-limited and must be prescribed by or in consultation with a physician who specializes in the condition being treated (nephrologist or rheumatologist); initial approval duration is 6 months and extended/renewal approvals are 1 year when continuation criteria are met.
- Prior authorization recommended for pharmacy benefit coverage of Lupkynis.
- Initial therapy must be prescribed by or in consultation with a nephrologist or rheumatologist.
- Initial approvals provided for 6 months (180 days); extended approvals for 1 year (365 days) when continuation criteria are met.
Not step therapy — concurrent use with cyclophosphamide or biologics unsupported
Lupkynis is not specified as step therapy; however, concurrent use with cyclophosphamide or with biologic agents is not recommended because safety and efficacy with these combinations have not been established.
- Concurrent use with cyclophosphamide or biologics has not been studied and is listed in Conditions Not Recommended for Approval.
- See appendix in policy for examples of biologics that should not be combined with Lupkynis.
Documentation may be requested — patient records, test results, provider credentials
The Company may request additional documentation to support medical necessity; providers must make requested supporting materials available upon request.
- Documentation that may be requested includes patient records, test results, and credentials of the provider ordering or prescribing the drug.
- The Company reserves the right to request additional documentation as part of its coverage determination process.
Denial risk — non‑medical necessity, investigational use, out‑of‑benefit, or inappropriate billing
The Company may deny reimbursement if the drug or services are determined to be not medically necessary, investigational/experimental, not within the members benefits, or if billing practices are inappropriate or excessive.
- Denial may occur when use is investigational/experimental or not within the scope of member benefits.
- A pattern of inappropriate or excessive billing or other practice can also lead to denial of reimbursement.
Key Definitions
Background
Lupkynis (voclosporin) is a calcineurin inhibitor immunosuppressant indicated for use in combination with background immunosuppressive therapy for adults with active lupus nephritis. The policy emphasizes that safety and efficacy have not been established when combined with cyclophosphamide or with biologic agents and that specialist involvement (nephrology or rheumatology) is recommended for initiation and monitoring.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.